強気
$74.60
シナリオ価格
$76.710
-2.071 (-2.70%)終値時点
Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions.
Globus Medical Inc is currently trading at $76.71, which is below the average analyst price target of $85 from RBC Capital. The stock has a forward P/E ratio of 13.87, indicating it is relatively undervalued compared to its earnings potential. However, insider selling has increased by 389.20% recently, which raises concerns about the stock's short-term outlook. Therefore, while the long-term growth potential remains, the current market sentiment and insider activity suggest a cautious approach, leading to a hold recommendation.
RBC Capital
$85
2026-10-01
RBC Capital
2026-10-01
目標株価
$85
Wells Fargo
$99
2026-08-07
Wells Fargo
2026-08-07
目標株価
$99
UBS
$82
2026-07-28
UBS
2026-07-28
目標株価
$82
Truist
$100
2026-07-16
Truist
2026-07-16
目標株価
$100
BMO Capital
$94
2026-07-08
BMO Capital
2026-07-08
目標株価
$94
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

Zacks Adds Five Stocks to Strong Buy List

Ecolab Reports Strong Q2 Performance Amid Cost Concerns

Globus Medical's Excelsius3D Receives CE Mark Approval

Globus Medical Launches CE-Marked Excelsius3D™ Imaging System

Globus Medical Acquires Higgs Boson Health to Enhance Patient Experience
Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Globus Medical Inc is currently trading at $76.71, which is below the average analyst price target of $85 from RBC Capital. The stock has a forward P/E ratio of 13.87, indicating it is relatively undervalued compared to its earnings potential. However, insider selling has increased by 389.20% recently, which raises concerns about the stock's short-term outlook. Therefore, while the long-term growth potential remains, the current market sentiment and insider activity suggest a cautious approach, leading to a hold recommendation.
13 analysts cover GMED: 5 rate it Buy, 7 Hold and 1 Sell. The average price target is 101.00.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。